Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk

Published on Oct 27, 2017in Nature Reviews Endocrinology28.8
· DOI :10.1038/NRENDO.2017.139
Ele Ferrannini110
Estimated H-index: 110
Anna Solini49
Estimated H-index: 49
(UniPi: University of Pisa)
Two phase III trials using the selective SGLT2 inhibitor dapagliflozin or the dual SGLT2/SGLT1 inhibitor sotagliflozin in patients with type 1 diabetes mellitus show similar clinical benefit (reduction of HbA1c, body weight, blood pressure and insulin dose). The risk of hypoglycaemia and diabetic ketoacidosis with these inhibitors can be managed by careful adjustment of insulin therapy.
📖 Papers frequently viewed together
2 Citations
43 Citations
7 Citations
#1Paresh Dandona (UB: University at Buffalo)H-Index: 102
#2Chantal Mathieu (Katholieke Universiteit Leuven)H-Index: 113
Last. William BiggsH-Index: 2
view all 167 authors...
Summary Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1...
147 CitationsSource
#1Sarah K. Lyons (BCM: Baylor College of Medicine)H-Index: 9
#2Julia M. Hermann (University of Ulm)H-Index: 16
Last. Reinhard W. Holl (University of Ulm)H-Index: 72
view all 12 authors...
The majority of those with type 1 diabetes (T1D) have suboptimal glycemic control (1–4); therefore, use of adjunctive pharmacotherapy to improve control has been of clinical interest. While noninsulin medications approved for type 2 diabetes have been reported in T1D research and clinical practice (5), little is known about their frequency of use. The T1D Exchange (T1DX) registry in the U.S. and the Prospective Diabetes Follow-up (DPV) registry in Germany and Austria are two large consortia of d...
27 CitationsSource
#1Satish K. Garg (University of Colorado Denver)H-Index: 70
#2Robert R. Henry (UCSD: University of California, San Diego)H-Index: 97
Last. Paul StrumphH-Index: 8
view all 15 authors...
BackgroundIn most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium–glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. MethodsIn this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin th...
196 CitationsSource
Sodium-glucose cotransporter-2 (SGLT2) is selectively expressed in the human kidney, where it executes reabsorption of filtered glucose with a high capacity; it may be overactive in patients with diabetes, especially in the early, hyperfiltering stage of the disease. As a therapeutic target, SGLT2 has been successfully engaged by orally active, selective agents. Initially developed as antihyperglycemic drugs, SGLT2 inhibitors have deployed a range of in vivo actions. Consequences of their primar...
131 CitationsSource
#1Bruce NealH-Index: 116
#2Vlado PerkovicH-Index: 93
Last. David R. Matthews (University of Oxford)H-Index: 84
view all 10 authors...
BackgroundCanagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. MethodsThe CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin o...
3,149 CitationsSource
#1Yehuda Handelsman (The American College of Financial Services)H-Index: 49
#2Robert R. Henry (UCSD: University of California, San Diego)H-Index: 97
Last. Matthew R. Weir (UMB: University of Maryland, Baltimore)H-Index: 96
view all 13 authors...
AACE = American Association of Clinical Endocrinologists ACE = American College of Endocrinology DKA = diabetic ketoacidosis EMA = European Medicines Agency FDA = U.S. Food and Drug Administration SGLT-2 = sodium glucosecotransporter 2 T1D = type 1 diabetes T2D = type 2 diabetes.
172 CitationsSource
#1Bernard Zinman (Lunenfeld-Tanenbaum Research Institute)H-Index: 8
#2Christoph Wanner (Boehringer Ingelheim)H-Index: 1
Last. Silvio E. InzucchiH-Index: 97
view all 12 authors...
BACKGROUND The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin...
5,361 CitationsSource
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium–glucose cotransporter 2 (SGLT2) inhibitors (1). This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System da...
377 CitationsSource
#1Kellee M. MillerH-Index: 30
#2Nicole C. FosterH-Index: 19
Last. William V. Tamborlane (Yale University)H-Index: 116
view all 8 authors...
To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from 75 years. The overall average ...
743 CitationsSource
#1Pablo Lapuerta (Lexicon Pharmaceuticals)H-Index: 22
#2Brian Zambrowicz (Lexicon Pharmaceuticals)H-Index: 50
Last. Arthur T. Sands (Lexicon Pharmaceuticals)H-Index: 38
view all 4 authors...
The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes. Development of SGLT2 inhibitors has been oriented around a desire for high selectivity for the SGLT2 protein relative to the SGLT1 protein. More recently, genetic and pharmacology research in mice has indicated that gastrointestinal SGLT1 inhibition may also be an appropriate therapeutic target to treat diabetes. Combining SGLT1 and SGLT2 inhibition in a single molecule wo...
73 CitationsSource
Cited By4
#1Simeon I. Taylor (UMB: University of Maryland, Baltimore)H-Index: 77
#2Jenny E. Blau (NIH: National Institutes of Health)H-Index: 11
Last. Amber L. Beitelshees (UMB: University of Maryland, Baltimore)H-Index: 33
view all 4 authors...
Summary Sodium-glucose co-transporter-2 (SGLT2) inhibitors have several beneficial effects in patients with type 2 diabetes, including glucose lowering, weight loss, blood pressure lowering, and a reduced risk of major adverse cardiovascular events. To address high unmet medical need via improved glycaemic control, several clinical trials have been done to assess the efficacy and safety of SGLT2 inhibitors in combination with insulin therapy in patients with type 1 diabetes. In this Personal Vie...
25 CitationsSource
#1Nie ZhangH-Index: 1
#2Zhi-Qun Gu (YZU: Yangzhou University)H-Index: 1
Last. Qi-Han Zheng (Jiangsu University)H-Index: 4
view all 6 authors...
Background: According to the centers for disease control and prevention, 14% of American adults have diabetes – 10% know it, and more than 4% go undiagnosed. Sotagliflozin is a new type of diabetes drug This study is to compare the efficacy of Sotagliflozin therapy for Diabetes Mellitus (DM) between week 24 with week 52.
1 CitationsSource
#1Kexin Li (NCU: Nanchang University)H-Index: 1
#2Gaosi Xu (NCU: Nanchang University)H-Index: 1
: 背景: 目前还不清楚葡萄糖协同转运体2(sodium glucose co-transporter 2,SGLT2)抑制剂对1型糖尿病的治疗是否为剂量依赖性。 方法: 从PubMed、EMBASE、the Cochrane Library、Web of Science和ClinicalTails搜集截至2018年8月份的随机对照试验(randomized clinical trials,RCT)。 结果: 本研究共纳入13个RCTs,包括5397名参与者。SGLT2抑制剂被证实对于1型糖尿病在血糖控制和减轻体重方面都是有效的。在不同剂量的亚组中,SGLT2抑制剂对糖化血红蛋白、体重、空腹血糖、日均血糖、基础胰岛素剂量、单剂胰岛素量、肾小球滤过率、收缩压都有降低作用,对平均血糖波动幅度和目标血糖范围内的时间百分比呈现剂量依赖性升高的特点,对总胰岛素剂量和尿糖排出量呈现非剂量依赖性的降低。SGLT2抑制剂没有诱导低血糖、严重低血糖、心血管疾病、骨折和全因死亡事件的风险,但是会增加不良反应、药物相关的不良反应、感染、糖尿病酮症酸中毒和肾脏疾病发生的概率,并且发生风险与剂量相关。 结论: ...
12 CitationsSource
#1Torben BiesterH-Index: 14
#2Olga KordonouriH-Index: 34
Last. Thomas DanneH-Index: 55
view all 3 authors...
: Use of sodium glucose cotransporter (SGLT) inhibitors are a well-established therapeutic option in type 2 diabetes (T2D) with a variety of proven therapeutic benefits. They have become a pillar of current treatment guidelines. In type 1 diabetes (T1D), initial exploratory studies have shown benefits in glycemic control, weight control, and cardiovascular risk parameters, leading to trials aiming for regulatory submission with several agents. Results from four 1-year trials, which included a to...
5 CitationsSource